1 / 30

Gestational Hypertension

Gestational Hypertension. Objectives Definitions Diagnosis Management Fetal / Maternal assessment Anti-Hypertensive therapy Anti-Seizure therapy Transport. Definitions Preexisting hypertension Gestational hypertension without proteinuria with proteinuria

jesus
Download Presentation

Gestational Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gestational Hypertension

  2. Objectives • Definitions • Diagnosis • Management • Fetal / Maternal assessment • Anti-Hypertensive therapy • Anti-Seizure therapy • Transport

  3. Definitions • Preexisting hypertension • Gestational hypertension • without proteinuria • with proteinuria • with proteinuria and adverse conditions • Preexisting hypertension with superimposed gestational hypertension with proteinuria • Unclassifiable antenatally

  4. Definitions • Hypertension • absolute value of  140/90 mmHg incremental rise of  30/15 mmHg diastolic BP of ³ 90 mmHg • sitting position with arm at heart level • appropriate size cuff • accurate mercury sphygmomanometer • Korotkoff sounds I and IV recorded • confirm BP in  4 hours unless very high

  5. Definitions • Proteinuria • urine protein  2+ on dipstick • urine protein  300 mg/d on 24 hour collection • proteinuria indicates glomerular dysfunction • 24 hour urine should be considered if urine protein  1+ on dipstick • edema may result from vasospasm and decreased oncotic pressure but this is not part of the definition

  6. Manifestations of Severity • Gestational hypertension with adverse conditions • diastolic BP > 110 mmHg • laboratory evidence -  platelets,  LFT's, uric acid • renal effects - proteinuria > 3 g/d, oliguria • CNS effects - seizure, headache, visual disturbances • other organ involvement - lung, liver, hematologic • fetal compromise - previously known as severe preeclampsia

  7. Incidence • 10% of all pregnancies complicated by hypertension • one third of these will have proteinuria • majority of preeclampsia in nulliparous patients • increased mortality risk in older gravidas • increased risk in first pregnancy with new partner • increased risk with preexisting hypertension, renal disease, diabetes mellitus • preeclampsia is a leading cause of direct maternal mortality

  8. Management • Stress reduction first • Assessment of mother and fetus • Treat blood pressure if dBP > 110 mmHg • Treat nausea and vomiting • Treat epigastric pain • Consider seizure prophylaxis • Consider timing/mode of delivery

  9. Stress Reduction • component of maternal BP is adrenergic • maternal discomfort must be minimized • several components • quiet, dimly lit, isolated room • well planned management protocol • clear explanation of plan to patient/family • minimization of negative stimuli • consistent, confident team approach nursing, obstetrics, anaesthesia, hematology, pediatrics

  10. Assessment of Mother - Clinical • Blood Pressure • assess severity • consistency in measuring • relationship of high BP to CVA not seizure • Central Nervous System • presence and severity of headache • vision disturbances - blurring, scotomata • tremulousness, irritability, hyperreflexia, somnolence • nausea and vomiting

  11. Assessment of Mother - Clinical • Hematologic • edema • bleeding, petechiae • Hepatic • RUQ and epigastric pain • nausea and vomiting • Renal • urine output and colour

  12. Assessment of Mother - Laboratory • Hematologic • hemoglobin, platelets, blood film • PTT, INR, fibrinogen, FDP • LDH, uric acid, bilirubin • Hepatic • ALT, AST • (glucose, ammonia to R/O AFLP) • Renal • proteinuria • creatinine, urea, uric acid

  13. Assessment of Fetus • Fetal movement • Fetal heart rate assessment • Ultrasound for growth • Biophysical profile • Amniotic fluid volume • Doppler flow studies

  14. Treatment • Nausea and Vomiting • antiemetic of choice • RUQ / Epigastric Pain • morphine 2 - 4 mg IV • antacid • minimize palpation

  15. Anti-hypertensive Therapy - Goals • minimize risk of maternal CVA • maximize maternal condition for safe delivery • gain time for further assessment • facilitate vaginal delivery if possible • prolong gestation where appropriate/feasible

  16. Anti-hypertensive Agents - Acute Therapy • Arteriolar Dilators • hydralazine • ß-Blockers • labetalol • Calcium Channel Blockers • nifedipine

  17. Anti-hypertensive Agents - Maintenance Therapy • Centrally Acting Sympatholytic Agents • methyl-dopa • ß-Blockers • atenolol • labetalol • Calcium Channel Blockers • nifedipine • ACE inhibitors are contraindicated in pregnancy

  18. Hydralazine • direct vasodilator, first line agent in acute settings • intravenous rapid onset useful for hypertensive crisis • can be used orally • Dosage - 5 mg IV test dose  5-10 mg q 20-40 minutes • Cautions - hypotension with fetal compromise may occur in slow acetylators and hypovolemic patients • Side Effects - may cause flushing, headache, tachycardia

  19. Methyldopa • centrally acting a2-receptor agonist, oral agent • long history of safe use in pregnancy, well tolerated • some concern regarding ability to control BP • not for use in acute settings • Dosage - 500 - 3000 mg po in 2 - 4 divided doses • Cautions - drug of choice in essential hypertension • Benefits - minimal side-effects and safe

  20. Atenolol • ß1-receptor antagonist, oral agent • cardiac output, renin release, vasomotor inhibitor • onset of action in 1 hour peak levels in 2-4 hours • long half life once a day dosing • Dosage - 50 -100 mg po OD • Cautions - DM, asthma, baseline FH, variability present • risk of IUGR with chronic use • Benefits - often only agent needed

  21. Labetalol • combined 1 and ß-blocker with ISA • intravenous rapid onset useful for hypertensive crisis • can be used orally • Dosage - maximum 300 mg IV dose • 20 mg IV followed by 20-80 mg IV titrated to BP • Cautions - concern re: fetal responses to hypoxia • Benefits - dependable, titratable, familiar

  22. Nifedipine • calcium channel blocker, oral agent • direct relaxation of vascular smooth muscle • rapid onset of action if regular capsule used • Dosage - Adalat-PA 10 mg bid 40 mg bid • Side Effects - magnesium toxicity, edema, flushing, headache, palpitations, tocolytic • use of short acting form discouraged

  23. Hypertensive Crisis • Stabilize severe hypertension • use hydralazine, ß-blocker, and/or Adalat-PA • goal maintain diastolic BP at 90 - 100 mmHg • monitor fetal status while treating BP • Seizure prophylaxis • Intravascular volume status • Foley catheter  seldom experience ARF • do not fluid overload  seldom require CVP line • Deliver

  24. Seizure Prophylaxis • difficult to predict who will seize • not directly related to degree of hypertension or level of proteinuria • high 'number needed to treat' to prevent seizure • agents not innocuous nor completely effective • MgSO4 is agent of choice when seizure prophylaxis is felt to be indicated

  25. Magnesium Sulfate • obstetrical standard but not used in other settings • superior to phenytoin for prophylaxis • superior to phenytoin or diazepam in preventing recurrence • Dosage - 4 g IV followed by 1 - 4 g / hour IV or 4 g IM q4h • Side Effects - weakness, paralysis, cardiac toxicity • Monitor - reflexes, respiration, level of consciousness

  26. Magnesium Sulfate - Overdose • close observation for side effects • weakness, respiratory paralysis, somnolence • especially high risk in those with oliguria or receiving Ca2+ channel blockers ANTIDOTE • stop magnesium infusion • 10% Calcium gluconate 10 mL IV over 3 minutes

  27. Transport • consider transport only if resources limited and maternal/fetal condition permits • maternal BP and symptoms stable • fetal status reassuring • appropriate anti-hypertensive agents started • MgSO4 started if appropriate • discuss with accepting centre and patient/family • MgSO4 and anti-hypertensives potentially fatal in overdose

  28. When to Deliver •  37 weeks with gestational hypertension •  34 weeks with severe gestational hypertension • < 34 weeks with any of: • poorly controlled dBP • lab evidence of worsening end-organ involvement • suspected fetal compromise • uncontrolled seizures • symptoms unresponsive to appropriate therapy

  29. Delivery - The Cure • timely delivery minimizes maternal and neonatal morbidity and mortality • optimize maternal status before interventions to deliver • delay delivery to gain fetal maturity and to allow transfer only when maternal and fetal condition allow it • gestational hypertension is a progressive disease, expectant management is potentially harmful in presence of severe disease or suspected fetal compromise

  30. Peri- and Postpartum Management • do not drop BP too low risking fetal compromise • do not fluid overload • epidural analgesia is favoured in the absence of low platelets or coagulopathy • multi-specialty approach • patient must be monitored post-partum

More Related